Showing 871-880 of 1601 results for "".
- Humira Biosimilar Simlandi Now Available in the UShttps://practicaldermatology.com/news/humira-biosimilar-simlandi-now-available-us/2463126/Teva Pharmaceuticals and Alvotech announced the availability of Simlandi (adalimumab-ryvk) injection in the US as an interchangeable biosimilar to Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as adult rheumatoid arthritis, j
- InnoCare Completes Patient Enrollment in Phase 2 Trial of ICP-488 for the Treatment of Psoriasishttps://practicaldermatology.com/news/innocare-completes-patient-enrollment-phase-2-trial-icp-488-treatment-psoriasis/2463108/InnoCare Pharma announced the completion of patient enrollment for the phase 2 clinical trial of ICP-488, a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor, for the treatment of psoriasis. The multicenter, randomized, double-blind, placebo-controlled phase 2 study aims to evaluate the e
- Study: Frequent Dermatologist Visits Boost Melanoma Survival Rateshttps://practicaldermatology.com/news/study-frequent-dermatologist-visits-boost-melanoma-survival-rates/2463097/New research suggests that patients with melanoma who engage in more frequent visits to the dermatologist show higher rates of survival. "Guidelines recommend that patients with melanoma undergo dermatologic examination at least annually," the authors wrote in the Journal of the American
- Consensus Statement Raises Awareness of CTCLhttps://practicaldermatology.com/news/consensus-statement-raises-awareness-ctcl/2463052/Kyowa Kirin, Inc. announced the publication of a patient-focused global consensus statement developed in collaboration with patient advocacy groups, calling on all healthcare authorities, hospitals, and clinicians to undertake 12 specific actions to enhance awareness, diagnosis, care, and support
- Merck Discontinues Testing of Experimental Skin Cancer Combo Therapyhttps://practicaldermatology.com/news/merck-discontinues-testing-experimental-skin-cancer-combo-therapy/2463022/Merck has announced the termination of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial, according to a news release from the company. The trial assessed the combination therapy's efficacy compared to KEYTRUDA alone as adjuvant treatment for patients w
- Research Grant Supports Animal-Free Testing for Botoxhttps://practicaldermatology.com/news/research-grant-supports-animal-free-testing-botox/2462979/The National Center for Advancing Translational Services (NCATS) and the US Food and Drug Administration (FDA) awarded a $2 million research grant to develop an advanced testing platform capable of assessing the potency of botulinum toxin without the need for animal testing, according to a press
- La Roche-Posay Unveils New Serum to Combat Dark Spotshttps://practicaldermatology.com/news/la-roche-posay-unveils-new-serum-combat-dark-spots/2462880/La Roche-Posay has announced the launch of its Mela B3 Dark Spot Serum & Mela B3 UV Daily Moisturizer SPF 30 products. Powered by Melasyl™, the manufacturer said in a news release, L'Oreal's multi-patented ingredient derived from 18 years of research, represents "a breakthrough in pig
- Allergan Calls for Real Patient Stories in New Campaignhttps://practicaldermatology.com/news/allergan-calls-real-patient-stories-new-campaign/2462879/Allergan Aesthetics has announced that it is inviting consumers to participate in upcoming campaigns for their flagship brands, including BOTOX® Cosmetic, the JUVÉDERM® collection of fillers. Both current and prospective patients can now apply for a chance to feature in future brand promo
- EPI Health Issues Voluntary Recall of Several Products Following Bankruptcyhttps://practicaldermatology.com/news/epi-health-issues-voluntary-recall-several-products-following-bankruptcy/2462869/EPI Health (Novan) is initiating a voluntary recall of various within-expiry human drug products as a result of the closures and discontinuation of the post-marketing quality, regulatory and pharmacovigilance activities for these marketed products. The moves comes after EPI filed Chapter 7 bankru
- Impact of Alopecia Areata on Pediatric Patients and Their Families: Insights from a Single-Center Study in Turkeyhttps://practicaldermatology.com/news/impact-alopecia-areata-pediatric-patients-and-their-families-insights-single-center-study-turkey/2462829/Alopecia areata (AA) is known to impact the health-related quality of life (HRQoL) of affected individuals, yet there is a paucity of research focusing on its effects specifically in pediatric patients and their families. To address this gap, researchers recently conducted a single-center cross-s